Frank X. Powers, DUDNYK
What can change is what advertisers depict in many of the DTC ads for serious health-threatening conditions: the happy patient.
Frank X. Powers
EXECUTIVE VICE PRESIDENT | DUDNYK
What can change is what advertisers depict in many of the DTC ads for serious health-threatening conditions: the happy patient. Perhaps the actual creative content could more accurately reflect life and what patients face, both from a medical and financial standpoint.
Frank X. Powers
I expect that the recent FDA rebuke will result in an increase in unbranded promotions and programs; more focused on disease and condition education rather than just brand awareness. This is good news for both patients and healthcare professionals, who will find better tools and resources to assist them in successful treatment outcomes. This presents a terrific opportunity for pharmaceutical marketers to leverage digital for its greatest strengths—the ability to truly engage consumers with deeper, more valuable content than they can provide through other promotional channels. Think of promotions like Wyeth's KnowMenopause.com or Novartis' AskAboutIron.com. Ideally, pharma marketers will integrate digital educational tools into a multi-touchpoint approach, building brand awareness through broadcast and print, while providing valuable educational resources through digital, both online as well as in the office.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
